After a meeting with the FDA, Agios Pharmaceuticals is planning to seek accelerated approval in the U.S. of mitapivat for ...
Prestigious Publication Reinforces risto-cel’s Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises ...
Global Blood Therapeutics Inc (NASDAQ: GBT) has submitted a supplemental marketing application to the FDA seeking accelerated approval for Oxbryta (voxelotor) for the treatment of Sickle Cell Disease ...
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ...
AGIO sinks 23% as mixed phase III data for mitapivat in SCD and an FDA review delay for thalassemia dent investors' confidence in its key growth drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results